BackBristol-Myers Squibb Company Ce Overview

Bristol-Myers Squibb Company Ce Profit Margin

Bristol-Myers Squibb Company Ce (CELG-RI) has a profit margin of 18.47%, above the sector sector average of 13.4%.

Get informed when a big investor buys or sells

+ Follow

Quarterly Profit Margin

16.54%
↓ 8.14% YoY

As of Sep 2026

Annual Profit Margin (TTM)

18.47%
↑ 46.94% YoY

Trailing 12 months ending Sep 2026

Average Profit Margin (Comparison Companies)

Loading

Profit Margin History

Loading

Profit Margin Comparison

Loading

Annual Profit Margin Growth Rate (%)

Loading

Bristol-Myers Squibb Company Ce (CELG-RI) FAQ

Bristol-Myers Squibb Company Ce posts a profit margin of 18.47% as of September 2026. That compares with 12.57% in the prior-year period — up 46.9% year over year. That is above the sector sector average of 13.4%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Bristol-Myers Squibb Company Ce's profit margin was 12.57%. The latest reading is 18.47% — a 46.9% year-over-year increase (period ending September 2026). Use the history and growth charts on this page for a longer lookback.

For its sector stocks, a profit margin near 13.4% is typical. Bristol-Myers Squibb Company Ce's 18.47% is higher that level. That is roughly 37.8% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Bristol-Myers Squibb Company Ce's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 18.47% as of September 2026; use YoY and peer views to separate noise from signal.

Context for CELG-RI's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 13.4%), and (3) consistency with growth and profitability. This page covers the first two; Bristol-Myers Squibb Company Ce's other metric pages and overview cover the third.